We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
Read MoreHide Full Article
Key Takeaways
Boston Scientific's Neuromodulation segment posted 6.8% operational sales growth in Q1 2025.
BSX saw strong gains from Intracept, Cartesia leads, and Lumina 3D within pain and brain therapies.
Boston Scientific expects continued growth in 2025, aided by Relievant and Axonics acquisitions.
Boston Scientific’s (BSX - Free Report) Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
In the first quarter of 2025, the Neuromodulation segment experienced 6.8% year-over-year operational sales growth, with the Brain franchise growing mid-single digits and the Pain franchise gaining high-single digits. Within the pain portfolio, the Intracept procedure (for chronic vertebrogenic low back pain) witnessed strong double-digit growth, backed by five-year clinical data showing long-term efficacy and cost-effectiveness of this treatment. Additionally, within deep brain stimulation (DBS), growth was driven by the launch of Cartesia leads and the rollout of the Lumina 3D programming algorithm in the United States.
Boston Scientific continues to invest in neuromodulation platforms and is strengthening commercial capabilities. The Neuromodulation segment is expected to show improvement as 2025 progresses, with organic contribution from recent acquisitions like Relievant and Axonics. Management expects the Neuromodulation business to grow above the market over time.
Progress of BSX’s Competitors in the Neuromodulation Field
In the first quarter of 2025, Abbott’s (ABT - Free Report) Neuromodulation segment demonstrated strategic progress through innovation and clinical advancement. The company began treating patients in its TRANSCEND clinical trial, a first-of-its-kind study designed to evaluate the use of DBS to address treatment-resistant depression. This initiative positions Abbott at the forefront of expanding DBS applications beyond movement disorders into mental health. The trial supports Abbott's long-term vision of developing transformative therapies for hard-to-treat neurological and psychiatric conditions.
Medtronic's (MDT - Free Report) Neuromodulation business grew low-double-digit year over year in the fiscal fourth quarter of 2025, significantly outperforming the market, driven by strong product launches and innovation. Within the Pain Stim business, the company experienced low double-digit growth, driven by the mid-teens United States growth, on the continued launch of the Inceptiv spinal cord stimulation (SCS) device. This device is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. The other big driver of Neuromodulation growth was the brain modulation business, which grew mid-single digit globally on the continued launch of Percept RC with BrainSense technology.
BSX Stock Price Performance
Shares of Boston Scientific have gained 33.3% in the past year compared with the industry’s growth of 9.6%. The S&P 500 composite has grown 9.1% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 33.11X, above the industry’s 21.09X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image: Shutterstock
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
Key Takeaways
Boston Scientific’s (BSX - Free Report) Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
In the first quarter of 2025, the Neuromodulation segment experienced 6.8% year-over-year operational sales growth, with the Brain franchise growing mid-single digits and the Pain franchise gaining high-single digits. Within the pain portfolio, the Intracept procedure (for chronic vertebrogenic low back pain) witnessed strong double-digit growth, backed by five-year clinical data showing long-term efficacy and cost-effectiveness of this treatment. Additionally, within deep brain stimulation (DBS), growth was driven by the launch of Cartesia leads and the rollout of the Lumina 3D programming algorithm in the United States.
Boston Scientific continues to invest in neuromodulation platforms and is strengthening commercial capabilities. The Neuromodulation segment is expected to show improvement as 2025 progresses, with organic contribution from recent acquisitions like Relievant and Axonics. Management expects the Neuromodulation business to grow above the market over time.
Progress of BSX’s Competitors in the Neuromodulation Field
In the first quarter of 2025, Abbott’s (ABT - Free Report) Neuromodulation segment demonstrated strategic progress through innovation and clinical advancement. The company began treating patients in its TRANSCEND clinical trial, a first-of-its-kind study designed to evaluate the use of DBS to address treatment-resistant depression. This initiative positions Abbott at the forefront of expanding DBS applications beyond movement disorders into mental health. The trial supports Abbott's long-term vision of developing transformative therapies for hard-to-treat neurological and psychiatric conditions.
Medtronic's (MDT - Free Report) Neuromodulation business grew low-double-digit year over year in the fiscal fourth quarter of 2025, significantly outperforming the market, driven by strong product launches and innovation. Within the Pain Stim business, the company experienced low double-digit growth, driven by the mid-teens United States growth, on the continued launch of the Inceptiv spinal cord stimulation (SCS) device. This device is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. The other big driver of Neuromodulation growth was the brain modulation business, which grew mid-single digit globally on the continued launch of Percept RC with BrainSense technology.
BSX Stock Price Performance
Shares of Boston Scientific have gained 33.3% in the past year compared with the industry’s growth of 9.6%. The S&P 500 composite has grown 9.1% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 33.11X, above the industry’s 21.09X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.